Case Reports in Oncology最新文献

筛选
英文 中文
Giant Clear Cell Renal Cell Carcinoma with Focal Chromophobe-Like Morphology in a Young Adult Presenting with Gastrointestinal Symptoms: A Case Report. 以胃肠道症状为表现的年轻成人巨透明细胞肾细胞癌伴局灶憎色样形态1例报告。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-30 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag020
Salem Hakouk, Omar Al-Abed, Mohammad Alaa Aldakak, Anas Saad, Ahmad Awaid, Lina Assad, Ibrahim Barghouth
{"title":"Giant Clear Cell Renal Cell Carcinoma with Focal Chromophobe-Like Morphology in a Young Adult Presenting with Gastrointestinal Symptoms: A Case Report.","authors":"Salem Hakouk, Omar Al-Abed, Mohammad Alaa Aldakak, Anas Saad, Ahmad Awaid, Lina Assad, Ibrahim Barghouth","doi":"10.1159/cro/abzag020","DOIUrl":"https://doi.org/10.1159/cro/abzag020","url":null,"abstract":"<p><strong>Introduction: </strong>Renal cell carcinoma is increasingly detected incidentally in the modern imaging era, and presentation as a giant renal mass is uncommon. Clear cell renal cell carcinoma is the most frequent histological subtype; however, unusual morphological patterns may create diagnostic challenges, particularly in young patients.</p><p><strong>Case presentation: </strong>A 31-year-old Syrian man presented with a 1-year history of recurrent colicky abdominal pain, postprandial dyspepsia, vomiting, and marked unintentional weight loss. Physical examination revealed a large firm left flank mass, while urinalysis showed microscopic hematuria without gross hematuria. Contrast-enhanced computed tomography demonstrated a giant left renal mass measuring approximately 18 × 17 × 23 cm, with a maximum diameter of about 24 cm on multiplanar images, heterogeneous enhancement, and central necrosis, without renal vein or inferior vena cava tumor thrombus. The patient underwent open transperitoneal radical nephrectomy with lymph node excision. Gross examination revealed a 3,200-g nephrectomy specimen containing a 23-cm tan-white mass with necrosis and hemorrhage extending to the renal sinus, capsule, and perinephric fat. Microscopy showed nests, tubules, and alveolar structures composed of polygonal cells with clear to pale eosinophilic cytoplasm and Fuhrman grade 2 nuclei. Immunohistochemistry demonstrated cytokeratin and CD10 positivity, with CK7 and CD117 negativity, supporting the diagnosis of clear cell renal cell carcinoma with focal eosinophilic/chromophobe-like morphology. Surgical margins were negative, and lymph nodes were uninvolved.</p><p><strong>Conclusion: </strong>This case highlights an unusual giant clear cell renal cell carcinoma in a young adult presenting predominantly with gastrointestinal symptoms. It emphasizes the importance of considering renal malignancy in patients with unexplained abdominal symptoms and the value of accurate pathological classification and long-term surveillance.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1713-1721"},"PeriodicalIF":0.7,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149262970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer. her2阳性晚期乳腺癌患者的曲妥珠单抗和帕妥珠单抗疑似治疗性眼毒性
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-22 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag014
Lahari Ramagiri, Kai C C Johnson, Margaret E Gatti-Mays, Ashley P Davenport
{"title":"Trastuzumab and Pertuzumab Suspected Therapy-Induced Ocular Toxicity in Patient Living with HER2-Positive Advanced Breast Cancer.","authors":"Lahari Ramagiri, Kai C C Johnson, Margaret E Gatti-Mays, Ashley P Davenport","doi":"10.1159/cro/abzag014","DOIUrl":"https://doi.org/10.1159/cro/abzag014","url":null,"abstract":"<p><strong>Introduction: </strong>Trastuzumab and pertuzumab, in combination with chemotherapy, are first-line anti-human epidermal growth factor 2 (HER2) therapies in the treatment of HER2-positive metastatic breast cancer. Although these therapies have been shown to improve the overall survival of patients, they can also be associated with adverse events; ocular toxicities have not been well-documented.</p><p><strong>Case presentation: </strong>This report outlines the case of a patient with a spectrum of new-onset transient ocular symptoms on pertuzumab-trastuzumab combination therapy that improved with cessation of the drug and recurred with trastuzumab monotherapy rechallenge. She developed ocular symptoms 2 years into her treatment course. Her principal ophthalmologic diagnosis was dry eye syndrome of bilateral lacrimal glands and keratoconjunctivitis sicca. Ultimately, she opted for close observation in lieu of continuing therapy. Her staging scans show no evidence of disease, and she denies eye-related symptom recurrence.</p><p><strong>Conclusion: </strong>Given the limited knowledge regarding the long-term ocular adverse events of HER2-targeted therapies, medical oncologists should routinely ask patients about new-onset or worsening ophthalmic symptoms.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1634-1642"},"PeriodicalIF":0.7,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary Salivary Clear Cell Carcinoma with Response to Checkpoint Inhibition: Case Report and Review of the Literature. 对检查点抑制有反应的原发性涎腺透明细胞癌:病例报告和文献回顾。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-15 eCollection Date: 2026-01-01 DOI: 10.1159/000552473
Samuel F Schaeffer, Matthew M Mirsky
{"title":"Primary Salivary Clear Cell Carcinoma with Response to Checkpoint Inhibition: Case Report and Review of the Literature.","authors":"Samuel F Schaeffer, Matthew M Mirsky","doi":"10.1159/000552473","DOIUrl":"10.1159/000552473","url":null,"abstract":"<p><strong>Introduction: </strong>Primary salivary clear cell carcinoma (CCC) is a rare tumor of the minor salivary glands that is often seen as low-grade and responsive to resection. Limited data exist for its response to systemic chemotherapy or immune therapy.</p><p><strong>Case presentation: </strong>A 76-year-old male presented with recurrent, widely metastatic salivary CCC over 3 years after local resection with bilateral selective neck dissections. Advanced imaging showed biopsy-confirmed metastasis to the omentum, lungs, pleural effusion, and lymph nodes. Stable disease was achieved with carboplatin/paclitaxel therapy, but treatment was not tolerated by the patient due to side effects. Patient has been treated with single-agent pembrolizumab for 12 cycles with continued disease control and improvement in effusion.</p><p><strong>Conclusion: </strong>Despite the low immunogenicity of this tumor, a clinically positive response was achieved with PD-(L)1 inhibition. More research is needed to identify systemic targeted therapies for CCC and tumors with low immunogenicity.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1760-1766"},"PeriodicalIF":0.7,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13668072/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149191467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Widespread Skeletal Fragility and Progressive Spinal Destruction Associated with Prolonged Tropomyosin Receptor Kinase Inhibitor Therapy: A Case Report. 长期原肌球蛋白受体激酶抑制剂治疗相关的广泛骨骼脆性和进行性脊柱破坏:一例报告。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-11 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag056
Hironori Yamaguchi, Hideyuki Ohzawa, Hideyo Miyato, Kenichi Ohshiro, Kensuke Yokoyama
{"title":"Widespread Skeletal Fragility and Progressive Spinal Destruction Associated with Prolonged Tropomyosin Receptor Kinase Inhibitor Therapy: A Case Report.","authors":"Hironori Yamaguchi, Hideyuki Ohzawa, Hideyo Miyato, Kenichi Ohshiro, Kensuke Yokoyama","doi":"10.1159/cro/abzag056","DOIUrl":"https://doi.org/10.1159/cro/abzag056","url":null,"abstract":"<p><strong>Introduction: </strong>Tropomyosin receptor kinase (TRK) inhibitors have demonstrated remarkable efficacy in patients with NTRK fusion-positive malignancies; however, their long-term effects on skeletal health remain incompletely understood.</p><p><strong>Case presentation: </strong>We report a 65-year-old woman with an ETV6-NTRK3 fusion-positive gastrointestinal stromal tumor who achieved sustained disease control during prolonged TRK inhibitor therapy. During treatment, she developed progressive skeletal fragility characterized by multiple atraumatic fractures, delayed fracture healing, and progressive lumbar spinal destruction consistent with Charcot-like neuropathic arthropathy. Neurological deterioration, including loss of ambulation, resulted from structural spinal instability rather than direct neurotoxicity. Although initial imaging findings raised suspicion of metastatic disease, serial CT, MRI, and FDG-PET/CT examinations supported a nonmalignant skeletal process in the setting of continued oncologic remission. Following discontinuation of TRK inhibitor therapy, neurological symptoms stabilized and radiographic evidence of fracture healing was observed.</p><p><strong>Conclusion: </strong>This case suggests that TRK inhibitor-associated skeletal toxicity may represent an on-target effect related to disruption of neuro-skeletal interactions. Long-term monitoring of bone health may be warranted in patients receiving prolonged TRK inhibitor therapy.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1704-1712"},"PeriodicalIF":0.7,"publicationDate":"2026-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688324/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete Response to Low-Dose Fam-Trastuzumab Deruxtecan in Recurrent Endometrial Cancer with Liver and Peritoneal Metastases: A Case Report. 低剂量fam -曲妥珠单抗德鲁西替康治疗复发性子宫内膜癌伴肝脏和腹膜转移的完全缓解:1例报告。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-10 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag048
Fang-Yu Wang, Cheng-Han Wu, Sung-Chao Chu, Chiu-Hsuan Cheng, Yen-Chang Chen, Han-Kuang Hsieh, Tso-Fu Wang
{"title":"Complete Response to Low-Dose Fam-Trastuzumab Deruxtecan in Recurrent Endometrial Cancer with Liver and Peritoneal Metastases: A Case Report.","authors":"Fang-Yu Wang, Cheng-Han Wu, Sung-Chao Chu, Chiu-Hsuan Cheng, Yen-Chang Chen, Han-Kuang Hsieh, Tso-Fu Wang","doi":"10.1159/cro/abzag048","DOIUrl":"https://doi.org/10.1159/cro/abzag048","url":null,"abstract":"<p><strong>Introduction: </strong>While fam-trastuzumab deruxtecan (T-DXd) has demonstrated significant efficacy in HER2-expressing solid tumors, its optimal dosing and tolerability in elderly or frail patients remain poorly defined. Evidence supporting upfront dose de-escalation in gynecologic malignancies is limited.</p><p><strong>Case presentation: </strong>We report a 73-year-old frail woman with recurrent, metastatic endometrial carcinoma featuring hepatic and peritoneal metastases, HER2 immunohistochemistry 3+, and high-level <i>ERBB2</i> amplification. Following progression on multiple platinum-taxane regimens, bevacizumab, surgery, hormonal therapy, and radiotherapy, the patient was treated with a fixed, reduced dose of T-DXd at 100 mg every 2 weeks (2.27 mg/kg per administration, approximately 63% of the standard-dose intensity). She achieved a complete radiological response by 6 months, with clinical improvement and no remarkable adverse events, sustaining a progression-free survival exceeding 16 months at last follow-up.</p><p><strong>Conclusion: </strong>This case illustrates a favorable response to dose-reduced T-DXd in a frail patient with strongly HER2-driven endometrial cancer, raising the possibility of individualized dosing strategies that warrant evaluation in larger prospective or retrospective cohorts.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1643-1649"},"PeriodicalIF":0.7,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SDHB-Related Carney-Stratakis Syndrome Presenting with a Gastric Gastrointestinal Stromal Tumor and a Clinically Suspected Paraganglioma: A Case Report and Literature Review. sdhb相关卡尼- stratakis综合征以胃肠道间质瘤和临床怀疑副神经节瘤为表现:1例报告及文献复习
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-08 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag050
Asuka Morishita, Kotaro Sugawara, Yoichi Yasunaga, Shuichiro Oya, Hiroya Mizutani, Koichi Yagi, Yoshifumi Baba
{"title":"SDHB-Related Carney-Stratakis Syndrome Presenting with a Gastric Gastrointestinal Stromal Tumor and a Clinically Suspected Paraganglioma: A Case Report and Literature Review.","authors":"Asuka Morishita, Kotaro Sugawara, Yoichi Yasunaga, Shuichiro Oya, Hiroya Mizutani, Koichi Yagi, Yoshifumi Baba","doi":"10.1159/cro/abzag050","DOIUrl":"https://doi.org/10.1159/cro/abzag050","url":null,"abstract":"<p><strong>Introduction: </strong>Carney-Stratakis syndrome (CSS) is a rare autosomal dominant hereditary tumor-predisposition syndrome characterized by succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GISTs) and paragangliomas. These tumors typically arise in younger patients, may occur synchronously or metachronously, and often show limited sensitivity to conventional tyrosine kinase inhibitors. Given the potential for multifocal disease, recurrence, and familial involvement, accurate clinicopathological assessment, genetic evaluation, and long-term surveillance are essential.</p><p><strong>Case presentation: </strong>A 36-year-old woman presented with a 7-month history of visual disturbance. Magnetic resonance imaging demonstrated a hypervascular tumor extending from the left jugular foramen to the carotid sheath, raising clinical suspicion of a paraganglioma and prompting biochemical and functional imaging evaluation. Plasma noradrenaline and dopamine levels were elevated, whereas 123I-metaiodobenzylguanidine scintigraphy showed no abnormal uptake. Fluorodeoxyglucose positron emission tomography incidentally identified a gastric submucosal tumor. Because placement of a lumboperitoneal shunt for intracranial hypertension was expected to increase the risk of infection and complicate subsequent abdominal surgery, gastric resection was prioritized. Laparoscopic-endoscopic cooperative surgery (LECS) was selected to facilitate local resection of the tumor near the esophagogastric junction while preserving the cardia; an intraoperative perforation necessitated conversion to classical LECS, and complete macroscopic resection was achieved. Histopathological examination demonstrated a multinodular epithelioid GIST positive for KIT and DOG1, with loss of SDHB expression, indicating an SDH-deficient GIST. Germline testing identified a pathogenic SDHB variant, supporting the diagnosis of CSS in the context of the clinically suspected paraganglioma. The jugular foramen lesion, for which no histological diagnosis was obtained, was managed conservatively, and delayed shunt placement improved the visual symptoms.</p><p><strong>Conclusion: </strong>This case highlights the importance of considering an SDH-related hereditary syndrome in a young patient with an SDH-deficient gastric GIST and a synchronous lesion clinically suggestive of paraganglioma. It also illustrates the value of genetic evaluation, explicit recognition of diagnostic uncertainty, and multidisciplinary treatment sequencing.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1663-1670"},"PeriodicalIF":0.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688335/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
High-Dose Busulfan and Thiotepa Followed by Autologous Stem Cell Transplantation for Refractory Choriocarcinoma with Central Nervous System Metastases: A Case Report. 大剂量布硫凡和硫替帕联合自体干细胞移植治疗难治性绒毛膜癌伴中枢神经系统转移1例。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-08 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag042
Julian Rapp, Reinhard Marks, Jesus Duque Afonso, Jürgen Finke, Michael Lübbert, Lucas Becker, Urs Würtemberger, Jamal Akkad, Uwe Martens, Cornelius F Waller, Tim Struessmann
{"title":"High-Dose Busulfan and Thiotepa Followed by Autologous Stem Cell Transplantation for Refractory Choriocarcinoma with Central Nervous System Metastases: A Case Report.","authors":"Julian Rapp, Reinhard Marks, Jesus Duque Afonso, Jürgen Finke, Michael Lübbert, Lucas Becker, Urs Würtemberger, Jamal Akkad, Uwe Martens, Cornelius F Waller, Tim Struessmann","doi":"10.1159/cro/abzag042","DOIUrl":"https://doi.org/10.1159/cro/abzag042","url":null,"abstract":"<p><strong>Introduction: </strong>Choriocarcinoma is particularly challenging to treat when it has metastasized to the central nervous system. Although metastatic choriocarcinoma generally responds well to therapy, brain metastases are associated with markedly poorer survival and can lead to severe neurological complications. One of the main challenges is that standard chemotherapy regimens, such as high-dose platinum derivatives and etoposide, do not effectively cross the blood-brain barrier, preventing adequate control in the central nervous system. For many, often relatively young patients, treatment options become severely limited when radiotherapy is contraindicated or has already been administered and surgery is not feasible.</p><p><strong>Case presentation: </strong>In this study, we describe the successful repurposing of a high-dose chemotherapy regimen consisting of busulfan and thiotepa in a patient with brain metastatic choriocarcinoma unresponsive to carboplatin and etoposide. These agents, widely used in central nervous system lymphoma, are well known for their ability to penetrate the blood-brain barrier. Treatment with this regimen resulted in stable disease and, most importantly, restored a very good quality of life for the patient.</p><p><strong>Conclusion: </strong>This case suggests a practical and novel therapeutic approach for managing choriocarcinoma with brain metastases, particularly in patients who have already received radiotherapy and are not candidates for further irradiation or surgery.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1378-1385"},"PeriodicalIF":0.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688449/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges in Managing Synchronous Advanced Prostate and Pancreatic Cancers: A Case Report. 治疗同步晚期前列腺癌和胰腺癌的挑战:一例报告。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-08 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag052
Fauna Herawati, Kevin Kantono, Taufik Indrawan
{"title":"Challenges in Managing Synchronous Advanced Prostate and Pancreatic Cancers: A Case Report.","authors":"Fauna Herawati, Kevin Kantono, Taufik Indrawan","doi":"10.1159/cro/abzag052","DOIUrl":"https://doi.org/10.1159/cro/abzag052","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate cancer (PCa) and pancreatic cancer (PC) are distinct malignancies with diverging epidemiological and prognostic profiles. PCa often mimics benign prostatic hyperplasia, while PC remains asymptomatic until advanced stages, complicating early detection. As cancer survivorship and screening improve, the incidence of synchronous multiple primary malignancies (MPMs) is rising, with emerging data suggesting a potential biological link between PCa and PC. Managing such cases requires a delicate balance of treatment sequencing and toxicity management. Reporting these rare encounters is vital for refining clinical strategies in complex oncologic presentations.</p><p><strong>Case presentation: </strong>This report details the clinical course of a 76-year-old male diagnosed synchronously with high-grade ductal PCa and pancreatic adenocarcinoma. Staging via PSMA PET-CT incidentally identified a pancreatic tail mass with an unusually high SUVmax of 5.2. Despite initiating standard androgen deprivation therapy, the aggressive ductal variant exhibited a \"PSA escape\" following treatment interruption. As the pancreatic lesion progressed metastatically, the patient's refusal of conventional chemotherapy and a lack of genomic profiling prompted a salvage, \"last-resort\" combination of pembrolizumab and olaparib. While this strategy achieved temporary biochemical stabilization and slowed tumor growth, the patient eventually succumbed to metabolic dysregulation and multi-organ failure.</p><p><strong>Conclusions: </strong>This case highlights the diagnostic challenges of MPM management, specifically rare PSMA-avidity in primary pancreatic tumors which can mimic metastatic spread. While empirical immunotherapy and PARP inhibitor combinations may offer temporary clinical benefit in resource-limited settings, they cannot substitute for biomarker-guided precision medicine. Success depends on strict therapeutic adherence and early multidisciplinary coordination.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1722-1731"},"PeriodicalIF":0.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688330/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyroid Artery Embolization as Salvage Therapy in Recurrent Papillary Thyroid Carcinoma: A Case Report. 甲状腺动脉栓塞治疗复发性甲状腺乳头状癌1例报告。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-08 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag047
Junjie Hao, Hao Jiang, Honghua Sun
{"title":"Thyroid Artery Embolization as Salvage Therapy in Recurrent Papillary Thyroid Carcinoma: A Case Report.","authors":"Junjie Hao, Hao Jiang, Honghua Sun","doi":"10.1159/cro/abzag047","DOIUrl":"https://doi.org/10.1159/cro/abzag047","url":null,"abstract":"<p><strong>Introduction: </strong>One case involved a 55-year-old male who was admitted to hospital with thyroid cancer.</p><p><strong>Case presentation: </strong>Chose interventional therapy (an unconventional treatment) after the conventional treatment failed.</p><p><strong>Conclusion: </strong>Eventually, the thyroid mass significantly decreased and achieved effective treatment.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1626-1633"},"PeriodicalIF":0.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685408/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149243268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utidelone plus PD-1 Inhibitors as Later-Line Combination Treatment in Advanced Solid Tumors after Failure of Multiple Standard Therapies: A Case Series. 乌替龙加PD-1抑制剂作为多种标准治疗失败后晚期实体瘤的后期联合治疗:一个病例系列。
IF 0.7
Case Reports in Oncology Pub Date : 2026-09-08 eCollection Date: 2026-01-01 DOI: 10.1159/cro/abzag051
Lisha Wu, Huisheng Chen, Zihang Lin, Haiwei Xiao, Tao Qin
{"title":"Utidelone plus PD-1 Inhibitors as Later-Line Combination Treatment in Advanced Solid Tumors after Failure of Multiple Standard Therapies: A Case Series.","authors":"Lisha Wu, Huisheng Chen, Zihang Lin, Haiwei Xiao, Tao Qin","doi":"10.1159/cro/abzag051","DOIUrl":"https://doi.org/10.1159/cro/abzag051","url":null,"abstract":"<p><strong>Introduction: </strong>The later-line treatment for advanced solid tumors that have progressed after multiple lines of therapy remains limited and challenging. Utidelone (UTD1), an analog of epothilone B, has shown significant antitumor activity in breast cancer undergone at least one previous chemotherapy in China. However, the combined therapeutic effect of UTD1 and programmed cell death protein-1 (PD-1) inhibitors in heavily pretreated solid tumors is unclear.</p><p><strong>Case presentation: </strong>Herein, we report a case series of 3 patients with heavily pretreated advanced solid tumors, including nasopharyngeal carcinoma and pulmonary adenocarcinoma, who had progressed after multiple lines of standard therapy. Treatment with UTD1 in combination with PD-1 inhibitors demonstrated promising efficacy. Individual progression-free survival times were 9, 5, and 6 months, respectively, with 2 patients achieving a partial response and one achieving stable disease. Although peripheral neuropathy was a common adverse event, it was generally manageable.</p><p><strong>Conclusion: </strong>Our case series highlights that UTD1 plus PD-1 inhibitors could become a novel later-line treatment option for patients with advanced solid tumors that have failed multiple standard therapies.</p>","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"19 1","pages":"1688-1697"},"PeriodicalIF":0.7,"publicationDate":"2026-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13688327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149263132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书